SPGPL gets USFDA approval for DFT,300mg

Representational image

Representational image

Global pharma major Cipla has received final approval from USFDA to market a generic equivalent of Tenofovir Disoproxil Fumarate 300mg tablets.

Tenofovir Disoproxil Fumarate is an AB-rated generic version of Gilead Sciences' Viread tablets. The drug will be made available for commercial shipment in the USA immediately.

The drug is also covered under U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and qualified for expedited review by the drug regulator.

At 11:02 hours IST, the stock price was quoting at Rs 804.55, up Rs 13.55, or 1.71 percent on the BSE.

Economic Survey 2017-18: 5 new facts on Indian economy
The recent projection by the World Bank shows that the Indian economy is expected to grow at 7.3 per cent in 2018-19. Economic Survey predicts services growth for FY18 at 8.3 percent, industry at 4.4 percent, and agri of 2.1 percent.

Gronkowski At Patriots Practice After Concussion Protocol
Gronkowski suffered a concussion in the first half [VIDEO ]and was ruled out of the game in the second half. They face the Philadelphia Eagles on February 4.

Boston Properties (BXP) Scheduled to Post Quarterly Earnings on Tuesday
Amica Retiree Medical Trust bought a new position in Boston Properties in the third quarter valued at approximately $105,000. The rating was downgraded by Morgan Stanley to "Underweight" on Tuesday, December 13. (NYSE:EXR) rating on Tuesday, May 23.

The two Indian companies are among the first wave of manufacturers launching the product in the USA market.

Cipla said the product is indicated in combination with other antiretroviral agents for the treatment of HIV -1 infection in adults and paediatric patients 12 years of age and older.

Pharmaceutical company Strides Shasun today said its wholly-owned subsidiary has received approval from the USA health regulator for tenofovir disoproxil fumarate tablets, used to treat HIV-1 infections in adults.

According to IMS data, the United States market for tenofovir disoproxil fumarate is approximately US$ 750 million.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.